contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bio-vitos-pharma-ab-the-european-patent-office-epo-grants-patent-that-is-important-to-bio-vitos-pharma

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Bio Vitos Pharma operates in the medical technology industry. The company develops and commercializes products for the detection of hemolysis in blood samples. The company has developed products that ensure that the hemolysis is detected at an early stage, which means that the blood sample can be taken care of immediately. The company also develops digital reading that is used as a complement to the main product. Bio Vitos Pharma was founded in 2010 and is headquartered in Karlstad.

Bio Vitos Pharma

The European Patent Office (EPO) has granted a patent for the treatment of heart failure patients with reduced ejection fraction, with oral iron succinate. The patent provides protection in ...

<div class="abstract">The European Patent Office (EPO) has granted a patent for the treatment of heart failure patients with reduced ejection fraction, with oral iron succinate. The patent provides protection in 26 countries and Bio Vitos Pharma owns the rights to this patent within the EU excluding the Nordic countries.</div>- This is very positive news for Bio Vitos Pharma. This enables strong protection for our iron succinate product Succifer which we are developing and increases our future revenue potential. Via Double Bond Pharmaceutical (DBP), Bio Vitos Pharma also owns the rights to other identical patent applications that are under review for other important geographic markets, and we believe this is a very good sign for these applications as well, says Jesper Birgemo, CEO at Bio Vitos Pharma.The clinical trials conducted by DBP show that iron succinate significantly improves iron absorption, iron saturation and iron storages in patients with heart failure and iron deficiency.Iron succinate is a less expensive alternative to the successful product Ferinject (which - as the name suggests - is administered intravenously). In 2022, the global sales of Ferinject amounted to approximately USD 500 million.For further information, contact:Bio Vitos Pharma AB (publ)Jesper Birgemo, CEOTel: +46(0) 70895 39 34About Bio Vitos Pharma ABBio Vitos Pharma develops, produces, and commercializes iron succinate for the treatment of iron deficiency within the parent company as well as a service for close-to-patient detection of hemolysis in blood samples within the framework of a wholly owned subsidiary, Hemcheck Management AB. The company is listed on the Nasdaq First North Growth Market.FNCA Sweden AB is the Certified Adviser to the company.Important informationThis information is such information that Bio Vitos Pharma is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on December 20, 2023 at 07.30

Bio Vitos Pharma AB: The European Patent Office EPO grants patent that is important to Bio Vitos Pharma

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!